NEUPHORIA THERAPEUTICS INC NEUP
COM · Common Stock · CUSIP 64136E102
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersBurlington, MA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 1.9m as of 2025-05-16, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $7.10.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2024 | 9 |
| Q1 2025 | 8 |
| Q2 2025 | 10 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2025 | 3 | 5 |
| Q2 2025 | 3 | 2 |
Biggest buyers
| CITADEL ADVISORS LLC | New | +14.6k |
| Prosperity Wealth Management, Inc. | Added | +2.5k |
| BANK OF AMERICA CORP /DE/ | New | +1 |
Biggest sellers
| AdvisorShares Investments LLC | Reduced | -1.9k |
| RHUMBLINE ADVISERS | Reduced | -382 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Lynx1 Capital Management LP
13D · may seek influence
no change · filed 2025-12-29
Stated purposeItem 4 of the Schedule 13D is hereby amended and supplemented as follows: On December 26, 2025, the Reporting Persons made an offer to the Board to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, certain intellectual-property-related assets of the Company in an all-cash transaction, or if the Company prefers, through the delivery by the Reporting Persons to the Company of shares of Common Stock of the Company with equivalent value (the "IP Rights Proposal"). The IP Rights Proposal is subject to the Reporting Persons' due diligence and agreement on definitive documentation for the acquisition. Neither the Reporting Persons nor the Company is obligated to complete a transaction in connection with the IP Rights Proposal, and th… Full filing |
16.3% |
| Shay Capital LLC 13G · passive investor new · filed 2025-10-31 | 7.3% |
| AdvisorShares Trust 13G · institution new · filed 2026-10-05 | 5.8% |
Fell to 5% or below in the last year: Coastlands Capital LP (4.2%, 2026-07-28), Baselake Partners, LP (4.1%, 2026-02-06)
Insider purchases and sales in Q2 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2025.
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| AdvisorShares Investments LLC 0.09% of their portfolio | 67.7k $480.9k | Reduced -1.9k |
| Lynx1 Capital Management LP 0.09% of their portfolio | 45.8k $325.2k | Unchanged |
| Prosperity Wealth Management, Inc. 0.08% of their portfolio | 29.8k $211.2k | Added +2.5k |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 14.6k $103.7k | New |
| Merck & Co., Inc. 0.03% of their portfolio | 10.0k $71.2k | Unchanged |
| Cyndeo Wealth Partners, LLC 0.00% of their portfolio | 10.0k $71.0k | Unchanged |
| RHUMBLINE ADVISERS 0.00% of their portfolio | 33 $234 | Reduced -382 |
| MORGAN STANLEY 0.00% of their portfolio | 7 $50 | Unchanged |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 1 $7 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. — of their portfolio | 0 $0 | Unchanged |